BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

<p>Table 1 Change from Baseline Figure 2 Improvements in Clinical Dementia Rating-Sum of Boxes Figure 3 Decrease of Neuroinflammatory Processes Figure 4 Age Deceleration Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to Significant GCP Violations and Protocol […]</p>
<p>The post <a href="https://forextv.com/top-news/biovie-announces-efficacy-data-from-phase-3-trial-of-ne3107-in-patients-with-mild-to-moderate-alzheimers-disease/">BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>